Acumen Research and Consulting estimate that the global Intranasal Drug and Vaccine Delivery market is expected to reach the market value of around US$ 60 Bn by 2028 and is anticipated to grow at a CAGR of around 7.1% in terms of revenue during the forecast period 2021 - 2028.
Drug distribution is a mechanism by which the patient's body absorbs a drug to create an important medicinal result. Different drug delivery mechanisms are used. The most common forms of drug distribution are nasal and pulmonary routes. The global drug procurement market is increasing at a significant pace as a result of expanded knowledge of the industry and technological developments in the sector. Intranasal drug administration refers to a nasal injection method of the prescribed drug. For acute or chronic treatments medications that are administered by nasal means may be recommended. Different types of medicines provided through the nasal cavity include anesthesia, pain relief medications, vaccines, vasoconstrictors, calcium supplements, antihistamines, snuffs, and more. The global intranasal drug delivery market can be divided into nasal sprays, ointments and treatments depending on the type of product. The clinical intranasal drug industry is categorized into analgesic infections, respiratory infections, pain control, osteoporosis, sexual dysfunction and vaccines dependent on medical uses. The global demand for the availability of intranasal drugs is growing at a substantial pace as the R&D for this distribution mode is rising. The utilization of the nasal cavity contributes to improved medication effectiveness. Intranasal administration of medications is also used to treat anxiety and depression.
The report provides analysis of global Intranasal Drug and Vaccine Delivery market for the period 2017-2028, wherein 2021 to 2028 is the forecast period and 2020 is considered as the base year.
Market Insights
One of the major factors driving the demand is growing preference for nasal drugs over parenteral and oral formulations for immediate relief.
Rising competition and technological developments are two of the main drivers of the sector. The clinical trials programs suggested for the treatment of different diseases have expanded spending in research and development.
Growing prevalence of chronic respiratory diseases raises the need for intranasal drugs and vaccination products, as medical providers also recommend due to the basic self-administration technologies. According to the CDC, 1 in 13 people suffer from asthma in 2020 and over 25 Mn Americans living and asthma. CDC has reported that an additional 14.2 million visits to clinics and 439,000 visits to clinics and 1.8 Mn annual trips to an emergency room accounted for asthma. Besides, thanks to their use in various formulations, including aqueous solutions, emulsions and suspensions, liquid distribution systems led the industry in 2020. The unit division is expected to experience positive growth as the treatment of multiple disabilities becomes gradually accepted. However, most of the vaccine formulations in production are single-dose formulations, although medical practitioners are generally prescribed with a single intranasal vaccine dosage.
Regional Stance
North America retained highest market share in 2020 and is expected to dominate the world's target market, owing to rising nasal distribution in the region, as well as improved health facilities. Moreover, many policy interventions and a raise in the consciousness of individuals are some of the essential factors that drive the global intranasal drug industry. Europe is expected to pursue Asia Pacific. India and China are expected to be Asia Pacific's rapidly emerging market for the production of intranasal medicines. This is thanks to the massive investments made in these regions by many main firms. The large pool of patients and expanded policy investment and construction of medical facilities are two of the key driving factors on the global intranasal drug supply demand in developing countries.
Key Players & Strategies
Participants include major global Aegis Therapeutics LLC, AstraZeneca PlcMedImmune, Inc., Alza Corporation, Baxter International, Inc., Becton, Dickinson and Company, GlaxoSmithKline Plc., Johnson & Johnson, Inc., and Others.
Business leaders pursue a range of approaches to achieve a greater share of the consumer business, including major spending in research and growth, product enhancement and regional expansion in developed countries. In addition, some companies concentrate on the launch of cost-effective generic nasal supply products, thus stimulating business expansion and increasing access to emergency treatments. In April 2020, in the United States, The FDA licensed Teva Pharmaceuticals' first generic naloxone nasal spray for opioid overdose.
Market Segmentation
Intranasal Drug and Vaccine Delivery Market By Product
Liquid Delivery Device
Powder Delivery Device
Pressurized Metered Dose Inhaler
Others
Intranasal Drug and Vaccine Delivery Market By Application
Neurological Disorder
Pain Management
Respiratory Disorders
Vaccination
Others
Intranasal Drug and Vaccine Delivery Market By End Use
Retail Outlets
Hospital Pharmacies
Online Platform
Intranasal Drug and Vaccine Delivery Market By Geography
North America
• U.S.
• Canada
Europe
• U.K.
• Germany
• France
• Spain
• Rest of Europe
Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa
• GCC
• South Africa
• Rest of Middle East & Africa
CHAPTER 1.Industry Overview of Intranasal Drug and Vaccine Delivery
1.1.Definition and Scope
1.1.1.Definition of Intranasal Drug and Vaccine Delivery
1.1.2.Market Segmentation
1.1.3.Years Considered for the Study
1.1.4.Assumptions and Acronyms Used
1.1.4.1.Market Assumptions and Market Forecast
1.1.4.2.Acronyms Used in Global Intranasal Drug and Vaccine Delivery Market
1.2.Summary
1.2.1.Executive Summary
1.2.2.Intranasal Drug and Vaccine Delivery Market By Product
1.2.3.Intranasal Drug and Vaccine Delivery Market By Application
1.2.4.Intranasal Drug and Vaccine Delivery Market By End Use
1.2.5.Intranasal Drug and Vaccine Delivery Market by Regions
CHAPTER 2.Research Approach
2.1.Methodology
2.1.1.Research Programs
2.1.2.Market Size Estimation
2.1.3.Market Breakdown and Data Triangulation
2.2.Data Source
2.2.1.Secondary Sources
2.2.2.Primary Sources
CHAPTER 3.Market Dynamics And Competition Analysis
3.1.Market Drivers
3.1.1.Driver 1
3.1.2.Driver 2
3.2.Restraints and Challenges
3.2.1.Restrain 1
3.2.2.Restrain 2
3.3.Growth Opportunities
3.3.1.Opportunity 1
3.3.2.Opportunity 2
3.4.Porter’s Five Forces Analysis
3.4.1.Bargaining Power of Suppliers
3.4.2.Bargaining Power of Buyers
3.4.3.Threat of Substitute
3.4.4.Threat of New Entrants
3.4.5.Degree of Competition
3.5.Market Concentration Ratio and Market Maturity Analysis of Intranasal Drug and Vaccine Delivery Market
3.5.1.Go To Market Strategy
3.5.1.1.Introduction
3.5.1.2.Growth
3.5.1.3.Maturity
3.5.1.4.Saturation
3.5.1.5.Possible Development
3.6.Technological Roadmap for Intranasal Drug and Vaccine Delivery Market
3.7.Value Chain Analysis
3.7.1.List of Key Manufacturers
3.7.2.List of Customers
3.7.3.Level of Integration
3.8.Cost Structure Analysis
3.8.1.Price Trend of Key Raw Materials
3.8.2.Raw Material Suppliers
3.8.3.Proportion of Manufacturing Cost Structure
3.8.3.1.Raw Material
3.8.3.2.Labor Cost
3.8.3.3.Manufacturing Expense
3.9.Regulatory Compliance
3.10.Competitive Landscape, 2020
3.10.1.Player Positioning Analysis
3.10.2.Key Strategies Adopted By Leading Players
CHAPTER 4.Manufacturing Plant Analysis
4.1.Manufacturing Plant Location and Establish Date of Major Manufacturers in 2020
4.2.R&D Status and Application Source of Intranasal Drug and Vaccine Delivery Major Manufacturers in 2020
CHAPTER 5.Intranasal Drug and Vaccine Delivery Market By Product
5.1.Introduction
5.2.Intranasal Drug and Vaccine Delivery Revenue By Product
5.2.1.Intranasal Drug and Vaccine Delivery Revenue (US$ Mn) and Forecast, By Product, 2017-2028
5.2.2.Liquid Delivery Device
5.2.2.1.Liquid Delivery Device Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
5.2.3.Powder Delivery Device
5.2.3.1.Powder Delivery Device Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
5.2.4.Pressurized Metered Dose Inhaler
5.2.4.1.Pressurized Metered Dose Inhaler Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
5.2.5.Others
5.2.5.1.Others Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
CHAPTER 6.Intranasal Drug and Vaccine Delivery Market Revenue By Application
6.1.Introduction
6.2.Intranasal Drug and Vaccine Delivery Revenue (US$ Mn) By Application
6.2.1.Intranasal Drug and Vaccine Delivery Revenue (US$ Mn) and Forecast By Application, 2017 - 2028
6.2.2.Neurological Disorder
6.2.2.1.Neurological Disorder Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
6.2.3.Pain Management
6.2.3.1.Pain Management Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
6.2.4.Respiratory Disorders
6.2.4.1.Respiratory Disorders Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
6.2.5.Vaccination
6.2.5.1.Vaccination Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
6.2.6.Others
6.2.6.1.Others Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
CHAPTER 7.Intranasal Drug and Vaccine Delivery Market By End Use
7.1.Introduction
7.2.Intranasal Drug and Vaccine Delivery Revenue (US$ Mn) By End Use
7.2.1.Intranasal Drug and Vaccine Delivery Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
7.2.2.Retail Outlets
7.2.2.1.Retail Outlets Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
7.2.3.Hospital Pharmacies
7.2.3.1.Hospital Pharmacies Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
7.2.4.Online Platform
7.2.4.1.Online Platform Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
CHAPTER 8.North America Intranasal Drug and Vaccine Delivery Market By Country
8.1.North America Intranasal Drug and Vaccine Delivery Overview
8.2.U.S.
8.2.1.U.S. Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017-2028
8.2.2.U.S. Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017-2028
8.2.3.U.S. Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017-2028
8.3.Canada
8.3.1.Canada Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017-2028
8.3.2.Canada Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017-2028
8.3.3.Canada Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017-2028
8.4.North America PEST Analysis
CHAPTER 9.Europe Intranasal Drug and Vaccine Delivery Market By Country
9.1.Europe Intranasal Drug and Vaccine Delivery Market Overview
9.2.U.K.
9.2.1.U.K. Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017-2028
9.2.2.U.K. Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017-2028
9.2.3.U.K. Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017-2028
9.3.Germany
9.3.1.Germany Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017-2028
9.3.2.Germany Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017-2028
9.3.3.Germany Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017-2028
9.4.France
9.4.1.France Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017-2028
9.4.2.France Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017-2028
9.4.3.France Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017-2028
9.5.Spain
9.5.1.Spain Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017-2028
9.5.2.Spain Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017-2028
9.5.3.Spain Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017-2028
9.6.Rest of Europe
9.6.1.Rest of Europe Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017-2028
9.6.2.Rest of Europe Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017-2028
9.6.3.Rest of Europe Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017-2028
9.7.Europe PEST Analysis
CHAPTER 10.Asia Pacific Intranasal Drug and Vaccine Delivery Market By Country
10.1.Asia Pacific Intranasal Drug and Vaccine Delivery Market Overview
10.2.China
10.2.1.China Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017 - 2028
10.2.2.China Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017 - 2028
10.2.3.China Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
10.3.Japan
10.3.1.Japan Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017 - 2028
10.3.2.Japan Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017 - 2028
10.3.3.Japan Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
10.4.India
10.4.1.India Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017 - 2028
10.4.2.India Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017 - 2028
10.4.3.India Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
10.5.Australia
10.5.1.Australia Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017 - 2028
10.5.2.Australia Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017 - 2028
10.5.3.Australia Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
10.6.South Korea
10.6.1.South Korea Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017 - 2028
10.6.2.South Korea Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017 - 2028
10.6.3.South Korea Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
10.7.Rest of Asia-Pacific
10.7.1.Rest of Asia-Pacific Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017 - 2028
10.7.2.Rest of Asia-Pacific Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017 - 2028
10.7.3.Rest of Asia-Pacific Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
10.8.Asia Pacific PEST Analysis
CHAPTER 11.Latin America Intranasal Drug and Vaccine Delivery Market By Country
11.1.Latin America Intranasal Drug and Vaccine Delivery Market Overview
11.2.Brazil
11.2.1.Brazil Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017 - 2028
11.2.2.Brazil Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017 - 2028
11.2.3.Brazil Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
11.3.Mexico
11.3.1.Mexico Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017 - 2028
11.3.2.Mexico Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017 - 2028
11.3.3.Mexico Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
11.4.Rest of Latin America
11.4.1.Rest of Latin America Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017 - 2028
11.4.2.Rest of Latin America Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017 – 2028
11.4.3.Rest of Latin America Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
CHAPTER 12.Middle East & Africa Intranasal Drug and Vaccine Delivery Market By Country
12.1.Middle East & Africa Intranasal Drug and Vaccine Delivery Market Overview
12.2.Saudi Arabia
12.2.1.Saudi Arabia Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017 - 2028
12.2.2.Saudi Arabia Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017 - 2028
12.2.3.Saudi Arabia Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
12.3.UAE
12.3.1.UAE Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017 - 2028
12.3.2.UAE Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017 - 2028
12.3.3.UAE Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
12.4.Rest of Middle East & Africa
12.4.1.Rest of Middle East & Africa Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Product, 2017 - 2028
12.4.2.Rest of Middle East & Africa Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By Application, 2017 - 2028
12.4.3.Rest of Middle East & Africa Intranasal Drug and Vaccine Delivery Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
CHAPTER 13.Player Analysis Of Intranasal Drug and Vaccine Delivery
13.1.Intranasal Drug and Vaccine Delivery Market Company Share Analysis
13.2.Competition Matrix
13.2.1.Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2.New Product Launches and Product Enhancements
13.2.3.Mergers And Acquisition In Global Intranasal Drug and Vaccine Delivery Market
13.2.4.Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14.COMPANY PROFILE
14.1.Aegis Therapeutics LLC
14.1.1.Company Snapshot
14.1.2.Business Overview
14.1.3.Financial Overview
14.1.3.1.Revenue (US$ Mn), 2020
14.1.3.2.Aegis Therapeutics LLC 2020 Intranasal Drug and Vaccine Delivery Business Regional Distribution
14.1.4.Product/ Service and Specification
14.1.5.Recent Developments & Business Strategy
14.1.6.Manufacturing Plant Footprint Analysis
14.2.AstraZeneca Plc
14.3.MedImmune, Inc.
14.4.Alza Corporation
14.5.Baxter International, Inc.
14.6.Becton, Dickinson and Company
14.7.GlaxoSmithKline Plc.
14.8.Johnson & Johnson, Inc.
14.9.Others
